Five reasons for using fenofibrate for the treatment of lipid disorders Artykuł przeglądowy
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
wrz 30, 2016
Słowa kluczowe:
fenofibrate, residual risk, microangiopathy, combination pharmacotherapy
##plugins.themes.bootstrap3.article.main##
Abstrakt
Fenofibrate significantly reduces the concentration of TG and increases the level of HDL-C while at the same time showing a pleiotropic effect. In addition, it inhibits further development of atherosclerosis and reduces the risk of macrovascular and microvascular complications, which improves prognosis, especially in patients with increased cardiovascular risk. Due to its high safety profile, fenofibrate is the drug of choice when used in combination with a statin.
##plugins.themes.bootstrap3.article.details##
Jak cytować
Wydra, W., & Kuch, M. (2016). Five reasons for using fenofibrate for the treatment of lipid disorders. Medycyna Faktów , 9(3(32), 236-237. Pobrano z https://journalsmededu.pl/index.php/jebm/article/view/2227
Numer
Dział
Artykuły
Copyright © by Medical Education. All rights reserved.
Bibliografia
1. Charakterystyka produktu leczniczego Lipanthyl Supra [online].
2. Okopień B, Krysiak R, Herman ZS. Effects of short-term fenofibrate treatment on circulating markers of inflammation and hemostasis in patients with impaired glucose tolerance. J Clin Endocrinol Metab 2006; 91(5): 1770-1778.
3. The ACCORD Study Group: Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus. N Engl J Med 2010; 362(17): 1563-1574.
4. Ansquer JC, Foucher C, Rattier S et al. Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DAIS). Am J Kidney Dis 2005; 45(3): 485-493.
5. Keech A, Simes RJ, Barter P. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005; 366(9500): 1849-1861.
6. The ACCORD Study Group and ACCORD Eye Study Group. Effects of Medical Therapies on Retinopathy Progression in Type 2 Diabetes. N Engl J Med 2010; 363(3): 233-244.
7. DAIS Investigators: Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet 2001; 357(9260): 905-910.
8. Grundy SM, Vega GL, Yuan Z et al. Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI trial). Am J Cardiol 2005; 95(4): 462-468.
2. Okopień B, Krysiak R, Herman ZS. Effects of short-term fenofibrate treatment on circulating markers of inflammation and hemostasis in patients with impaired glucose tolerance. J Clin Endocrinol Metab 2006; 91(5): 1770-1778.
3. The ACCORD Study Group: Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus. N Engl J Med 2010; 362(17): 1563-1574.
4. Ansquer JC, Foucher C, Rattier S et al. Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DAIS). Am J Kidney Dis 2005; 45(3): 485-493.
5. Keech A, Simes RJ, Barter P. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005; 366(9500): 1849-1861.
6. The ACCORD Study Group and ACCORD Eye Study Group. Effects of Medical Therapies on Retinopathy Progression in Type 2 Diabetes. N Engl J Med 2010; 363(3): 233-244.
7. DAIS Investigators: Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet 2001; 357(9260): 905-910.
8. Grundy SM, Vega GL, Yuan Z et al. Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI trial). Am J Cardiol 2005; 95(4): 462-468.